IDEAYA Biosciences to Present First Median Overall Survival Data from Phase 2 Trial of the Darovasertib / Crizotinib Combination in Metastatic Uveal Melanoma at the 2025 Society for Melanoma Research Congress
IDEAYA Biosciences (NASDAQ:IDYA) announced the acceptance of an abstract for oral presentation at the 2025 Society for Melanoma Research Congress in Amsterdam. The presentation will feature the first-ever median overall survival data from their Phase 1/2 trial evaluating the combination of darovasertib and crizotinib in first-line metastatic uveal melanoma (mUM).
The study, known as OptimUM-01, includes data from over 40 patients. Dr. Meredith McKean from Sarah Cannon Research Institute will present the findings at the congress, which takes place from October 25-28, 2025. The detailed data from the abstract will be disclosed at a future date.
IDEAYA Biosciences (NASDAQ:IDYA) ha comunicato l'accettazione di un abstract per una presentazione orale al 2025 Society for Melanoma Research Congress ad Amsterdam. La presentazione includer脿 i primi dati mai riportati sulla sopravvivenza mediana globale dello studio di Fase 1/2 che valuta la combinazione di darovasertib e crizotinib nella prima linea del melanoma uveale metastatico (mUM).
Lo studio, denominato OptimUM-01, comprende dati provenienti da oltre 40 pazienti. La dottoressa Meredith McKean del Sarah Cannon Research Institute presenter脿 i risultati al congresso, in programma dal 25 al 28 ottobre 2025. I dati completi dell'abstract saranno resi noti in una data successiva.
IDEAYA Biosciences (NASDAQ:IDYA) anunci贸 la aceptaci贸n de un abstract para presentaci贸n oral en el 2025 Society for Melanoma Research Congress en 脕msterdam. La presentaci贸n incluir谩 los primeros datos sobre la supervivencia global mediana de su ensayo de Fase 1/2 que eval煤a la combinaci贸n de darovasertib y crizotinib en primera l铆nea de melanoma uveal metast谩sico (mUM).
El estudio, denominado OptimUM-01, contiene datos de m谩s de 40 pacientes. La Dra. Meredith McKean del Sarah Cannon Research Institute presentar谩 los hallazgos en el congreso, que se celebrar谩 del 25 al 28 de octubre de 2025. Los datos detallados del abstract se divulgar谩n en una fecha posterior.
IDEAYA Biosciences (NASDAQ:IDYA)電� 鞎旍姢韰岆ゴ雼挫棎靹� 鞐措Μ電� 2025 Society for Melanoma Research Congress鞐愳劀 甑憪 氚滍憸 齑堧鞚� 毂勴儩霅橃棃雼り碃 氚滍憸頄堨姷雼堧嫟. 鞚措矆 氚滍憸鞐愳劀電� 1彀� 鞝勳嫚 鞝勳澊靹� 韽弰毵夗潙靸夓(mUM)鞐愳劀 雼る氚旍劀韹半笇鞕� 韥Μ臁绊嫲雼� 氤戩毄鞚� 韽夑皜頃� 1/2靸� 鞁滍棙鞚� 斓滌磮 欷戧皠 鞝勳泊靸濎〈旮瓣皠(median overall survival) 雿办澊韯�臧� 瓿店皽霅╇媹雼�.
OptimUM-01搿� 鞎岆牑歆� 鞚� 鞐瓣惮鞐愲姅 40氇� 鞚挫儊鞚� 頇橃瀽 雿办澊韯瓣皜 韽暔霅橃柎 鞛堨姷雼堧嫟. Sarah Cannon Research Institute鞚� Meredith McKean 氚曥偓臧� 2025雲� 10鞗� 25鞚茧秬韯� 28鞚缄箤歆� 鞐措Μ電� 頃欗殞鞐愳劀 瓴瓣臣毳� 氚滍憸頃� 鞓堨爼鞛呺媹雼�. 齑堧鞚� 靸侅劯 雿办澊韯半姅 鞚错泟鞐� 氚滍憸霅� 鞓堨爼鞛呺媹雼�.
IDEAYA Biosciences (NASDAQ:IDYA) a annonc茅 l'acceptation d'un abstract pour une pr茅sentation orale au 2025 Society for Melanoma Research Congress 脿 Amsterdam. La pr茅sentation mettra en avant les premi猫res donn茅es rapport茅es sur la survie globale m茅diane de leur essai de phase 1/2 茅valuant la combinaison darovasertib et crizotinib en premi猫re ligne du m茅lanome uv茅al m茅tastatique (mUM).
L'茅tude, appel茅e OptimUM-01, inclut des donn茅es provenant de plus de 40 patients. La Dre Meredith McKean du Sarah Cannon Research Institute pr茅sentera les r茅sultats lors du congr猫s, qui se tiendra du 25 au 28 octobre 2025. Les donn茅es d茅taill茅es de l'abstract seront divulgu茅es ult茅rieurement.
IDEAYA Biosciences (NASDAQ:IDYA) gab bekannt, dass ein Abstract f眉r eine m眉ndliche Pr盲sentation beim 2025 Society for Melanoma Research Congress in Amsterdam angenommen wurde. Die Pr盲sentation wird die ersten jemals berichteten Daten zum medianen Gesamt眉berleben aus ihrer Phase-1/2-Studie zeigen, die die Kombination von Darovasertib und Crizotinib in der Erstlinienbehandlung von metastasiertem Uveal-Melanom (mUM) untersucht.
Die Studie mit der Bezeichnung OptimUM-01 enth盲lt Daten von 眉ber 40 Patienten. Dr. Meredith McKean vom Sarah Cannon Research Institute wird die Ergebnisse auf dem Kongress pr盲sentieren, der vom 25. bis 28. Oktober 2025 stattfindet. Die ausf眉hrlichen Daten des Abstracts werden zu einem sp盲teren Zeitpunkt bekannt gegeben.
- None.
- None.
Details of the Presentation are as follows:
Title (Abstract #209): First reported overall survival results from a phase 1/2 study of darovasertib (OptimUM-01) plus crizotinib as first-line treatment for metastatic uveal melanoma
Presenter: Dr. Meredith McKean, MD, MPH; Director, Melanoma and Skin Cancer Research at Sarah Cannon Research Institute
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer. Our approach integrates expertise in small-molecule drug discovery, structural biology and聽bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease.聽 We have built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates, or ADCs, for molecularly defined solid tumor indications. Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective, and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer.
Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to (i) the potential therapeutic benefits of IDEAYA therapeutics, including combination therapies; and (ii) the timing and content of an oral/poster presentation at the 2025 SMRC related to data from a Ph 1/2 trial of darovasertib in combination with crizotinib in 1L mUM. Such forward-looking statements involve substantial risks and uncertainties that could cause IDEAYA's preclinical and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including IDEAYA's programs' in early or late stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, IDEAYA's ability to successfully establish, protect and defend its intellectual property, and other matters that could affect the sufficiency of existing cash to fund operations. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's Annual Report on Form 10-K dated February 18, 2025 and any current and periodic reports filed with the
Investor and Media Contact
IDEAYA Biosciences
Joshua Bleharski, Ph.D.
Chief Financial Officer 聽
[email protected]
View original content to download multimedia:
SOURCE IDEAYA Biosciences, Inc.
FAQ
What will IDEAYA Biosciences (IDYA) present at the 2025 SMR Congress?
How many patients were included in IDEAYA's (IDYA) Phase 1/2 trial of darovasertib?
When and where will IDEAYA (IDYA) present their melanoma trial results?
Who will present IDEAYA's (IDYA) clinical trial data at the 2025 SMR Congress?
